Apar Jindal1, Subramanian Suriyan2, Suresh Sagadevan3, Meenakshi Narasimhan4, Aruna Shanmuganathan5, Viswambhar Vallabhaneni6, Ragulan Rajalingam6. 1. Junior Consultant, Respiratory Critical Care and Sleep Medicine, VIMHANS Primamed Hospital , Nehru Nagar, Delhi, India . 2. Associate Professor, Department of Respiratory Medicine, Chettinad Hospital and Research Institute , Kelambakkam, Chennai, Tamilnadu, India . 3. Post Graduate Student, Department of Respiratory Medicine, Chettinad Hospital and Research Institute , Kelambakkam, Chennai, Tamilnadu, India . 4. Professor and Head of Department, Department of Respiratory Medicine, Chettinad Hospital and Research Institute , Kelambakkam, Chennai, Tamilnadu, India . 5. Professor, Department of Respiratory Medicine, Chettinad Hospital and Research Institute , Kelambakkam, Chennai, Tamilnadu, India . 6. Assistant Professor, Department of Respiratory Medicine, Chettinad Hospital and Research Institute , Kelambakkam, Chennai, Tamilnadu, India .
Abstract
INTRODUCTION: Even though the links between upper and lower airway had been of interest to clinicians since long back, it has not attracted the attention of the researchers till recent past. But the evidence is still far from conclusive, due to limited number of randomized controlled trials available on subjects with concomitant allergic rhinitis and asthma. This gap in the knowledge is even more conspicuous in Indian population. AIM: The current study is conducted with an objective of comparing the efficacy and tolerability of intranasal Fluticasone and oral Montelukast in treatment of allergic rhinitis and bronchial asthma. MATERIALS AND METHODS: The study was a prospective randomized, single blinded, comparative, parallel group study, with two intervention groups conducted in a tertiary teaching hospital in Chennai, Southern India. One hundred and twenty patients diagnosed with concomitant diagnosis of allergic rhinitis and bronchial asthma was randomly allocated to either Fluticasone propionate aqueous nasal spray or oral Montelukast group. RESULTS:Out of total 120 subjects recruited, 108 subjects were included in the final analysis. The mean reduction in asthma and rhinitis symptom scores and improvement in PEFR was higher for Group A, compared to Group B during all the follow-up periods. No statistically significant difference was observed in proportion of subjects reporting exacerbations in the current study. Both the treatments were well tolerated. CONCLUSION: Addition of intranasal Fluticasone propionate to Salmeterol plus Fluticasone is beneficial in improving asthma control, allergic rhinitis control and lung functions as compared to oral Montelukast. Thereby the use of intranasal Fluticasone Propionate in comparison to oral Montelukast in control of Allergic Rhinitis is justified as per the significant improvement in outcome measures.
RCT Entities:
INTRODUCTION: Even though the links between upper and lower airway had been of interest to clinicians since long back, it has not attracted the attention of the researchers till recent past. But the evidence is still far from conclusive, due to limited number of randomized controlled trials available on subjects with concomitant allergic rhinitis and asthma. This gap in the knowledge is even more conspicuous in Indian population. AIM: The current study is conducted with an objective of comparing the efficacy and tolerability of intranasal Fluticasone and oral Montelukast in treatment of allergic rhinitis and bronchial asthma. MATERIALS AND METHODS: The study was a prospective randomized, single blinded, comparative, parallel group study, with two intervention groups conducted in a tertiary teaching hospital in Chennai, Southern India. One hundred and twenty patients diagnosed with concomitant diagnosis of allergic rhinitis and bronchial asthma was randomly allocated to either Fluticasone propionate aqueous nasal spray or oral Montelukast group. RESULTS: Out of total 120 subjects recruited, 108 subjects were included in the final analysis. The mean reduction in asthma and rhinitis symptom scores and improvement in PEFR was higher for Group A, compared to Group B during all the follow-up periods. No statistically significant difference was observed in proportion of subjects reporting exacerbations in the current study. Both the treatments were well tolerated. CONCLUSION: Addition of intranasal Fluticasone propionate to Salmeterol plus Fluticasone is beneficial in improving asthma control, allergic rhinitis control and lung functions as compared to oral Montelukast. Thereby the use of intranasal Fluticasone Propionate in comparison to oral Montelukast in control of Allergic Rhinitis is justified as per the significant improvement in outcome measures.
Entities:
Keywords:
Intra nasal steroids; Leukotriene antagonists; Nasobronchial allergy
Authors: Robert S Zeiger; Steven R Bird; Michael S Kaplan; Michael Schatz; David S Pearlman; E John Orav; Carolyn M Hustad; Jonathan M Edelman Journal: Am J Med Date: 2005-06 Impact factor: 4.965
Authors: Richard D O'Connor; Richard Stanford; Courtney Crim; Steven W Yancey; Lisa Edwards; Kathleen A Rickard; Paul Dorinsky Journal: Ann Allergy Asthma Immunol Date: 2004-12 Impact factor: 6.347
Authors: Paul H Ratner; William C Howland; Raiqua Arastu; Edward E Philpot; Kristofer C Klein; Charlotte A Baidoo; Melissa A Faris; Kathleen A Rickard Journal: Ann Allergy Asthma Immunol Date: 2003-05 Impact factor: 6.347
Authors: Sorif Uddin; Augustin Amour; David J Lewis; Chris D Edwards; Matthew G Williamson; Simon Hall; Lisa A Lione; Edith M Hessel Journal: BMC Immunol Date: 2021-12-17 Impact factor: 3.615